Pharmacovigilance outsourcing solves capacity challenges, but it doesn’t replace the regulatory accountability sponsors hold for governance and decision-making. This article explores why meaningful partnerships, long-term senior safety involvement, and strong governance design are essential in a modern PV system, and why biopharma teams choose Perspective Pharmacovigilance for support.

Pharmacovigilance is evolving beyond compliance. For growing biopharma organizations, success depends on scalable safety systems, transparent partnerships, and proactive risk management that keep pace with innovation. This article explores how Perspective Pharmacovigilance helps companies align scientific excellence with operational flexibility to support safe, confident growth.

Episode 2 of the Perspectives Webinar Series explores how structured benefit-risk can drive clearer planning, stronger governance, and more confident decision-making for small and mid-sized biopharma teams. This session highlights how appropriate structure creates measurable operational value without unnecessary complexity.

Transitioning from clinical development to commercial launch is one of the most critical and complex phases for any biotech company. This article explores how strategic pharmacovigilance planning, from early-stage design to post-marketing oversight, helps ensure a seamless and compliant transition across global markets.

Perspective Pharmacovigilance has expanded its leadership network with experts who bring decades of regulatory and pharmacovigilance experience from the U.S. Food and Drug Administration. This addition strengthens our ability to help biopharma innovators design smarter risk management strategies, build inspection-ready systems, and navigate regulatory expectations with confidence.

The EU’s new pharmacovigilance regulation introduces major changes for biotech and pharma companies operating in Europe. Learn what’s behind Regulation 2025/1466, what it means for safety governance, and how to prepare for full compliance by February 2026.

Why structured benefit-risk is more than a regulatory expectation. This webinar introduces PPV’s pragmatic, hybrid approach for biotech innovators, designed to improve decision-making, align with regulators, and adapt across the product lifecycle.

Perspective Pharmacovigilance, Inc. and RegDev, Inc. Announce Strategic Partnership to Provide Best-in-Class Molecule to Market Services

Perspective Pharmacovigilance Strengthens EU Leadership Team with Appointment of Kieran O'Donnell as Managing Director and EU Practice Lead